Browsing Tag
Essential Tremor
2 posts
Could essential tremor finally be entering a new treatment era after Praxis’ Phase 3 results?
Praxis Precision Medicines’ Phase 3 results could reshape essential tremor treatment and re-rate the neurology market. Read what this means for investors.
Praxis Precision Medicines (NASDAQ: PRAX) surges 229% after breakthrough Phase 3 data in essential tremor
Praxis stock soared 229% on Phase 3 results for ulixacaltamide in essential tremor. Find out what this means for PRAX’s future and investor sentiment.